- Home
- JFU vs XTLB Comparison
JFU vs XTLB Comparison
Compare JFU & XTLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFU
- XTLB
- Stock Information
- Founded
- JFU 2006
- XTLB 1993
- Country
- JFU China
- XTLB Israel
- Employees
- JFU N/A
- XTLB N/A
- Industry
- JFU Finance: Consumer Services
- XTLB Biotechnology: Pharmaceutical Preparations
- Sector
- JFU Finance
- XTLB Health Care
- Exchange
- JFU Nasdaq
- XTLB Nasdaq
- Market Cap
- JFU 17.8M
- XTLB 16.3M
- IPO Year
- JFU 2019
- XTLB 2005
- Fundamental
- Price
- JFU $1.37
- XTLB $1.25
- Analyst Decision
- JFU
- XTLB
- Analyst Count
- JFU 0
- XTLB 0
- Target Price
- JFU N/A
- XTLB N/A
- AVG Volume (30 Days)
- JFU 6.8K
- XTLB 7.4K
- Earning Date
- JFU 01-01-0001
- XTLB 03-25-2025
- Dividend Yield
- JFU N/A
- XTLB N/A
- EPS Growth
- JFU N/A
- XTLB N/A
- EPS
- JFU 0.09
- XTLB N/A
- Revenue
- JFU $40,614,155.00
- XTLB $46,000.00
- Revenue This Year
- JFU N/A
- XTLB N/A
- Revenue Next Year
- JFU N/A
- XTLB N/A
- P/E Ratio
- JFU $15.56
- XTLB N/A
- Revenue Growth
- JFU N/A
- XTLB N/A
- 52 Week Low
- JFU $1.13
- XTLB $0.85
- 52 Week High
- JFU $3.75
- XTLB $4.99
- Technical
- Relative Strength Index (RSI)
- JFU 39.00
- XTLB 38.83
- Support Level
- JFU $1.38
- XTLB $1.17
- Resistance Level
- JFU $1.56
- XTLB $1.38
- Average True Range (ATR)
- JFU 0.08
- XTLB 0.13
- MACD
- JFU -0.02
- XTLB -0.00
- Stochastic Oscillator
- JFU 0.00
- XTLB 25.20
About JFU 9F Inc.
9F Inc is a financial account platform integrating and personalizing financial services in China. It provides a range of financial products and services across online lending, wealth management, and payment facilitation, all integrated under a single digital financial account. The company generates the majority of its revenue from Loan facilitation services. All its revenues are generated from the People's Republic of China.
About XTLB XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.